The objective of this study is to compare reduced-dose prasugrel and standard dose
clopidogrel in patients older than 74 years with ACS, including non-ST-elevation (NSTEACS)
and ST-elevation (STEMI) patients, undergoing early PCI. The primary endpoint of the trial
will be the one-year composite of (all-cause)death, myocardial infarction, stroke and
re-hospitalization due to cardiovascular reasons or bleeding.
Phase:
Phase 4
Details
Lead Sponsor:
Arcispedale Santa Maria Nuova-IRCCS
Collaborators:
ANMCO Italian Association of Hospital Cardiologist Italian Society of Invasive Cardiology